Archive. Year 2011
Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
12/23/2011 | Press Release
Ampio Pharmaceuticals Announces Registered Direct Common Stock Offering of Approximately $9.436 Million
12/21/2011 | Press Release
Ampio Responds to Recent Publications by Anonymous Short Sellers
12/16/2011 | Press Release
Ampio Pharmaceuticals Awarded European Patent that Strengthens Intellectual Property Protection for its key drug Ampion™
12/07/2011 | Press Release
Ampio Pharmaceuticals Announces Agreement to Acquire Key Drug Delivery Technology
12/05/2011 | Press Release
Ampio Pharmaceuticals Expands Patent Portfolio of Drugs for Treating Inflammatory Diseases
11/16/2011 | Press Release
Ampio Pharmaceuticals Announces Positive Results on Ampion™ Trial for Relief of Nasal Inflammation
11/10/2011 | Press Release
Ampio Pharmaceuticals (AMPE) to Ring The NASDAQ Stock Market Opening Bell
10/31/2011 | Press Release
Favorable Clinical Trial Results for Ampion™ in Treatment of Osteoarthritis (AIK) Allows Testing as a Monotherapy Against "Standard of Care," Ahead of Schedule
10/26/2011 | Press Release
Ampio Pharmaceuticals Announces a Proof of Concept Trial of Danazol in the Treatment of Allergic Rhinitis Supports Mechanism of Action of Optina™
10/18/2011 | Press Release
Ampio Pharmaceuticals, Inc. Completes Treatment Phase of the Ampion™-in-Knee Clinical Trial for Osteoarthritis
10/13/2011 | Press Release
Ampio Announces the Presentation of a Publication on Ampion™, its Drug Candidate to Address Human Inflammation, at the American Association of Orthopedic Surgery
10/10/2011 | Press Release
Ampio Pharmaceuticals Receives Notice of Allowance of its Two Patent Applications on the Combination of Zertane with Erectile Dysfunction Drugs in Canada
09/28/2011 | Press Release
Ampio Announces Positive Results From 12-Week Open Label Extension Study of Zertane in Patients With Premature Ejaculation
09/26/2011 | Press Release
Q&A Exclusive: Ampio's Leadership Aggressively Focused on Significant Licensing Opportunities and Getting Trials Completed
09/14/2011 | Press Release
Ampio Pharmaceuticals' Executes License and Development Agreement with Daewoong Co. Ltd. to Commercialize Zertane in South Korea
09/08/2011 | Press Release
Zertane Clinical Results Published in the Journal European Urology
08/30/2011 | Press Release
Ampio Pharmaceuticals Announces Treatment of First Patient in Phase 1b Ampion-In -Knee (AIK) Trial for Osteoarthritis in Australia
07/05/2011 | Press Release
Ampio Pharmaceuticals, Inc. Releases Results From Phase III Clinical Trial of Zertane™ for the Treatment of Premature Ejaculation (PE), the Most Prevalent Form of Male Sexual Dysfunction
06/27/2011 | press release
Ampio Pharmaceuticals Set to Join Russell 3000 Index
06/16/2011 | Press Release
Ampio Pharmaceuticals, Inc. Appoints Dr. David R. Stevens as New Independent Director
06/08/2011 | Press Release
Ampio Pharmaceuticals, Inc. Announces Initiation of Phase 1B Clinical Trial for Its Anti-inflammatory Drug Ampion
05/31/2011 | Press Release
Ampio Pharmaceuticals, Inc. Completes Evaluation of Data From Phase III Clinical Trials of Zertane for Treatment of the Most Common Male Sexual Dysfunction, Premature Ejaculation
05/23/2011 | Press Release
Ampio Pharmaceuticals, Inc. to Begin Trading on the NASDAQ Capital Market
05/19/2011 | Press Release
Ampio Pharmaceuticals, Inc. Receives Approval to List on the NASDAQ Capital Market
05/17/2011 | Press Release
Ampio Pharmaceuticals, Inc. Announces Final Closing of Private Placement and Filing of Resale Registration Statement
04/19/2011 | Press Release
Ampio Pharmaceuticals, Inc. Announces Appointment of New Chief Financial Officer to be Effective April 4, 2011
04/01/2011 | Press Release
Years: 2013 | 2012 | 2011 | 2010
Learn More About:
Premature Ejaculation (PE)
Premature ejaculation is a distressing male sexual dysfunction that is more common than erectile dysfunction (ED) and has a major impact on the quality of life for men and their sexual partners.
Diabetic Retinopathy
A complication of diabetes mellitus that damages the retina in the eyes and leads to blindness
Diabetic Nephropathy
A progressive complication of diabetes mellitus that leads to end-stage renal disease (ESRD) requiring kidney transplantation or chronic dialysis
| AMPE Stock Quote - delayed | ||
| Last | Change | |
| AMPE | 5.06 |  0.02 (0.39%) |
Ampio News
05/13/2013 | Press Release
Ampio Pharmaceuticals Announces Participation at the UBS Global Healthcare Conference
04/25/2013 | Press Release
04/02/2013 | Press Release